Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Accured Expenses (2016 - 2025)

Enanta Pharmaceuticals' Change in Accured Expenses history spans 14 years, with the latest figure at -$5.2 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 77.87% year-over-year to -$5.2 million; the TTM value through Dec 2025 reached -$2.2 million, down 21.32%, while the annual FY2025 figure was $58000.0, 101.03% up from the prior year.
  • Change in Accured Expenses reached -$5.2 million in Q4 2025 per ENTA's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.7 million in Q3 2021 to a low of -$6.7 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is -$197550.0, with a median of $669500.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 939.85% in 2021, then crashed 277.88% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $4.2 million in 2021, then crashed by 256.89% to -$6.6 million in 2022, then fell by 2.08% to -$6.7 million in 2023, then surged by 56.8% to -$2.9 million in 2024, then crashed by 77.87% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Change in Accured Expenses are -$5.2 million (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).